AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 28.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 335,934 shares of the biotechnology company’s stock after selling 133,926 shares during the quarter. Dimensional Fund Advisors LP’s holdings in AnaptysBio were worth $8,418,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Great Point Partners LLC increased its position in AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after purchasing an additional 82,648 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in AnaptysBio during the first quarter worth about $420,000. Octagon Capital Advisors LP acquired a new stake in AnaptysBio during the fourth quarter worth about $2,570,000. Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio during the first quarter worth about $1,221,000. Finally, First Light Asset Management LLC increased its position in AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after purchasing an additional 446,372 shares during the last quarter.

Insiders Place Their Bets

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the transaction, the insider now directly owns 11,618 shares in the company, valued at $406,630. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,940 shares of company stock valued at $1,251,836. 33.70% of the stock is owned by corporate insiders.

AnaptysBio Trading Down 2.9 %

ANAB stock opened at $33.00 on Tuesday. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $41.31. The company’s 50 day moving average is $35.37 and its two-hundred day moving average is $28.63. The stock has a market cap of $901.53 million, a P/E ratio of -5.37 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. On average, equities research analysts predict that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ANAB shares. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. Truist Financial increased their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $51.10.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.